Business

Penumbra makes minimally invasive devices that pull blood clots out of vessels — stroke, pulmonary embolism, deep-vein thrombosis — plus embolization and vascular-access tools, from one U.S. base at ~$1.4B revenue growing ~20% a year. It clears the universe screen (NYSE common stock, $12.6B cap), is not an auto or Chinese name, but carries darling-grade multiples. The orienting fact: on January 14, 2026 it signed a definitive merger to be acquired by Boston Scientific at $374 a share.

What Penumbra is

Penumbra designs, builds and sells catheters and mechanical systems that remove clots and occlude vessels from inside the bloodstream. Founded in Alameda, California in 2004 and public on the NYSE since 2015, it treats a defined set of life-threatening vascular conditions — ischemic stroke, pulmonary embolism (PE), deep-vein thrombosis (DVT), acute limb ischemia, plus aneurysms and hemorrhagic stroke [1]. In two sentences: it is a focused U.S. medical-device maker that pioneered computer-assisted vacuum ("aspiration") thrombectomy and now competes across the neuro and peripheral vascular field; it sells consumable devices to hospitals, ~90% through its own direct sales force, and books the whole company as one operating segment [2].

Sources: FY2025 10-K, Consolidated Statements of Operations and geographic disaggregation [3]; headcount [4].

Revenue splits two ways. By product, thrombectomy — the clot-removal franchise led by the Indigo and Penumbra systems — generated $947.9M in 2025, and embolization and access (coils, occlusion devices, guide catheters) generated $455.7M [5]. By geography, the United States accounted for $1,091.8M and all international markets $311.9M [6]. The business is a razor-and-blade consumables model: single-use catheters and systems used per procedure, manufactured almost entirely in-house at Alameda and Roseville, California, with a new plant under construction in Costa Rica [7].

Source: derived from reported figures, FY2021–FY2025 10-Ks (revenue = gross profit + cost of revenue); FY2025 10-K Consolidated Statements of Operations [8].

The shape is a clean growth chart: revenue up roughly fivefold over the decade, a ~20% compound rate, with no down year. Profitability has lagged and lurched — GAAP net income was negative or near-zero in most years through 2022 (FY2024 alone carried a $76.9M impairment and heavy inventory write-downs), then jumped to $177.7M in 2025 as the top line and gross margin recovered. This is a business whose value has always been priced on growth and market opportunity, not on current cash returns.

The Boston Scientific merger

The dominant fact about Penumbra today is that it has agreed to sell itself. On January 14, 2026 it signed a definitive Agreement and Plan of Merger with Boston Scientific Corporation — one of its own named competitors — at an enterprise value of approximately $14.5 billion, valuing each Penumbra share at $374, payable ~73% in cash and ~27% in Boston Scientific stock (3.8721 shares per Penumbra share, subject to proration) [9]. The deal is expected to close by the end of 2026, subject to Penumbra stockholder and regulatory approval [10]; as of mid-2026 it had board approval from both sides and remained pending those approvals.

That reframes the stock. At the $321.19 close on July 31, 2026, Penumbra traded about 14% below the $374 cash-equivalent deal value — a merger-arbitrage spread reflecting time-to-close, deal risk, and the floating Boston Scientific stock leg, not a market judgment on the standalone business. The price sits near the top of its range and above where it traded before the announcement: shares had fallen from a $303.76 peak (February 2025) to a $225.54 trough (November 2025), a −26% drawdown, then re-rated on the January bid. There is no forced-selling capitulation here; the anatomy of the tape belongs to the Dislocation and Clock tabs, but the orienting point is that the price today is a claim on a takeout, and in year 10 the company will not exist as an independent public entity.

Market structure

Penumbra sits in the neuro-and-peripheral-vascular device market as the focused innovator, not the incumbent. Its own filing names its most notable competitors as Boston Scientific, Medtronic, Stryker (now including Inari Medical), and Terumo, plus several private companies, and describes them plainly as "large, well-capitalized companies with longer operating histories and greater resources than we have" [11]. Stryker's 2025 acquisition of Inari Medical — a direct PE/DVT thrombectomy competitor — and now Boston Scientific's move on Penumbra itself show the giants consolidating the space around them.

The market is best read as an oligopoly of diversified large-caps into which Penumbra has carved a product-leadership position — the opposite of the dominant, price-setting incumbent the framework prizes for year-10 durability. The countervailing evidence is real: the clinical need is genuinely essential and the addressable market is large and under-penetrated. Penumbra cites approximately 2.15 million clot incidences a year in the United States alone, "the vast majority of which do not currently receive mechanical thrombectomy intervention" [12], and roughly 200,000 of ~700,000 annual U.S. ischemic strokes as treatable by thrombectomy [13].

The moat pillars the Durability tab will weigh cut both ways. Regulatory entry barriers exist — FDA 510(k)/PMA clearance, CE marking, ISO 13485 quality systems — but they gate every competitor equally and the larger players clear them routinely. Capital intensity is moderate (in-house manufacturing, $63.7M of FY2025 capex) rather than a fortress-scale barrier. The operating history is ~22 years — real, but short of the 30–50-year franchises the framework leans on. What protects Penumbra is intellectual property, accumulated clinical evidence, and physician relationships — an execution-and-innovation moat, which the framework treats as weaker than structural or regulatory-entry protection. The essential product and expanding TAM support higher year-10 revenue; the challenger position, the youth, and the pending absorption into a competitor argue against very high conviction on a standalone basis.

Universe screen

Penumbra clears both gates. U1 (geography): it is a U.S.-domiciled company headquartered in California, listed on the NYSE under common stock (CUSIP/ISIN US70975L1070) — not an ADR, not a Chinese issuer [14]. U2 (market cap): at $321.19 on July 31, 2026 across 39.29M shares, the market capitalization is $12.62B, above the >$10B line — a clean pass, roughly 26% above the threshold, with the pending deal implying a $14.5B enterprise value.

Source: market cap from fit_features (price $321.19 on 2026-07-31 × 39.29M shares); listing facts per the FY2025 10-K cover and Overview cited above.

Exclusion screen — first pass

X1 — auto/OEM: clear. Penumbra is a pure medical-device manufacturer; no automotive exposure.

X4 — consensus darling: flagged. Penumbra carries the darling signature the framework screens out. Standalone, the $12.62B cap is ~9.0x FY2025 revenue; the $374 deal price is ~10.3x revenue on enterprise value and ~83x FY2025 GAAP EPS of $4.52 — premium, high-growth medtech multiples, not value multiples. The chart is textbook bottom-left-to-top-right (revenue up ~5x in a decade, no down year), and the story is a secular-growth, "this changes stroke care" narrative that a strategic acquirer has now validated with a takeover premium. The counter-facts: the standalone multiple sat below the very top of premium medtech (names such as Intuitive Surgical trade richer), FY2024 GAAP earnings were near zero on impairments, and the stock now trades as a merger-arb spread rather than on momentum. Even so, the positioning — richly valued growth compounder that consensus and now an acquirer love — is the profile of a name where a fear-driven dislocation buyer has no edge.

S1 — China exposure: immaterial. Penumbra has no material China revenue or asset dependence. It sells ~90% of revenue through its own direct sales force; China is served through a technology-licensing arrangement with a local distribution partner (fixed payments plus royalties), embedded within the ~10% of revenue that runs through distributors [15]. With total international revenue of $311.9M (22% of the company) spread across Europe, Canada, Australia, Singapore and distributor markets [16], China is a small piece of a minority segment — a sensitivity worth naming, not a dependence.

Promotional-CEO (X2) and structural-decline (X3) checks are not this tab's to settle; nothing surfaced here contradicts them — revenue is rising, not declining — and they are carried by Self-Help and Durability.